UF010

UF010 is a selective inhibitor of class I HDAC. UF010 has cytotoxicity to cancer cells and reduces neuroinflammation in the hippocampus. UF010 can be used for the research of neurological diseases[1][2][3].

Product Specifications

CAS Number

[537672-41-6]

UNSPSC

12352005

Hazard Statement

H302

Target

HDAC; Interleukin Related; JAK; MyD88; NF-κB; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/UF010.html

Purity

99.83

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(NNCCCC)C1=CC=C(Br)C=C1

Molecular Formula

C11H15BrN2O

Molecular Weight

271.15

Precautions

H302

References & Citations

[1]Mattar P, et al. A Casz1–NuRD complex regulates temporal identity transitions in neural progenitors [J]. Scientific reports, 2021, 11 (1) : 3858.|[2]Pulya S, et al. Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer [J]. European Journal of Medicinal Chemistry, 2022, 238: 114470.|[3]Dai Y, et al. Classical HDACs in the regulation of neuroinflammation[J]. Neurochemistry International, 2021, 150: 105182.|[4]Yang C X, et al. The inhibitory effects of class I histone deacetylases on hippocampal neuroinflammatory regulation in aging mice with postoperative cognitive dysfunction [J]. European Review for Medical & Pharmacological Sciences, 2020, 24 (19) .|[5]Pulya S, et al. Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer [J]. Journal of Medicinal Chemistry, 2023, 66 (17) : 12033-12058.